Author:
Li Zhigui,Huang Yuqian,Zhao Rui,Cui Yaping,Zhou Yong,Wu Xiaoting
Publisher
Springer Science and Business Media LLC
Reference35 articles.
1. Jemal, A. et al. Global cancer statistics. CA: a cancer journal for clinicians 61, 69–90 (2011).
2. Schmoll, H. J. et al. ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making. Annals of oncology: official journal of the European Society for Medical Oncology 23, 2479–2516 (2012).
3. Botrel, T. E., Clark, L. G., Paladini, L. & Clark, O. A. Efficacy and safety of bevacizumab plus chemotherapy compared to chemotherapy alone in previously untreated advanced or metastatic colorectal cancer: a systematic review and meta-analysis. BMC cancer 16, 677 (2016).
4. Liang, R. F. & Zheng, L. L. The efficacy and safety of panitumumab in the treatment of patients with metastatic colorectal cancer: a meta-analysis from five randomized controlled trials. Drug design, development and therapy 9, 4471–4478 (2015).
5. Saltz, L. B. et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 26, 2013–2019 (2008).
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献